Study of Ranolazine in Myotonia Congenita, Paramyotonia Congenita and Myotonic Dystrophy Type 1
- Conditions
- Myotonia CongenitaParamyotonia CongenitaMyotonic Dystrophy 1
- Interventions
- Registration Number
- NCT02251457
- Lead Sponsor
- Ohio State University
- Brief Summary
The purpose of this study is to gather preliminary data to determine if ranolazine is a safe and effective treatment for the symptoms of myotonia congenital, paramyotonia congenita, and myotonic dystrophy type 1. The duration of the study is 5 weeks.
- Detailed Description
Recent advances in the understanding of myotonia congenita have identified potential areas that could possibly respond to treatment in a drug study. The drug ranolazine (trade name Ranexa) is a FDA-approved medication to treat chest pain in patients with heart disease. Ranolazine has been studied in mice with myotonia congenita. The data from this animal model suggest that ranolazine may improve the symptoms and signs of myotonia. All individuals that participate will be placed on active drug. The investigators want to see if this drug is safe to take without causing too many side effects for people with myotonia congenita, paramyotonia congenital and myotonic dystrophy type 1. Participants will go to The Ohio State University for study visits. Participants will take ranolazine for four weeks. Participants can expect a total of 4 study visits and 2 phone calls over the 5 week period.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 35
- Diagnosis of myotonia congenital, paramyotonia congenital or Myotonic Dystrophy Type 1 established by genetic testing in the subject or in a first-degree relative.
- Clinically evident myotonia
-
Contraindications to ranolazine use:
-
for fungus infection: ketoconazole (Nizoral), itraconazole (Sporanox, Onmel)
-
for infection: clarithromycin (Biaxin)
-
for depression: nefazodone
-
for HIV: nelfinavir (Viracept), ritonavir (Norvir), lopinavir and ritonavir (Kaletra), indinavir (Crixivan), saquinavir (Invirase).
-
for tuberculosis (TB): rifampin (Rifadin), rifabutin (Mycobutin), rifapentine (Priftin)
-
for seizures: phenobarbital, phenytoin (Phenytek, Dilantin, Dilantin-125), carbamazepine (Tegretol)
-
the herbal supplement St. John's wort
- you have scarring (cirrhosis) of your liver
-
-
Concurrent use of mexiletine, lacosamide, acetazolamide, phenytoin, quinine, procainamide, Saint John wort or tocainide. Patients who were previously treated with these medications may participate. They need to be off of the medication for at least a week prior to enrollment.
-
QTc >470 ms for men and >480 ms for women.
-
Women who are pregnant or breastfeeding
-
Direct family history of sudden cardiac death
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description ranolazine Ranolazine ranolazine 500mg, twice daily for two weeks; 1000mg twice daily for 2 weeks
- Primary Outcome Measures
Name Time Method Questionnaires: Short Form Health Survey (SF-36) and Individualized Neuromuscular Quality of Life Questionnaire (INQoL) 1 month quality of life measurements for overall health and neuromuscular disease
Muscle tasks 1 month The subject is observed and timed while rising from an arm chair, walking 3 meters, turning, walking back, and sitting down again
Electromyography (EMG) Myotonia 1 month To see if the electrical potentials produced by the muscle fibers change.
- Secondary Outcome Measures
Name Time Method Electrocardiogram (ECG) 1 month to measure heart function and observe QT interval (a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle)
Trial Locations
- Locations (1)
The Ohio State University Wexner Medical Center
🇺🇸Columbus, Ohio, United States